Drug Profile
BXCL 901
Alternative Names: BXCL901Latest Information Update: 28 Jun 2021
Price :
$50
*
At a glance
- Originator BioXcel Corporation
- Class Antianaemics
- Mechanism of Action Enzyme inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diamond-Blackfan syndrome
Most Recent Events
- 28 Jun 2021 No recent reports of development identified for preclinical development in Diamond-Blackfan-syndrome in USA
- 22 May 2017 Preclinical trials in Diamond-Blackfan syndrome in USA before May 2017 (Bioxcel pipeline, May 2017)